ACADIA Pharmaceuticals Inc.

ACAD | NASDAQ

Price Alert Chart Builder DCF Calculator

$26.39

-$0.90 (-3.30%)

At close: Sep 21, 2026, 4:00 PM ET

$26.39

$0 (+0.02%)

After-hours: Sep 21, 2026, 7:30 PM ET

Overview Rating Statistics Financials Earnings Analysts Ownership Profile

-3.30%

(1D)

Rating

Updated: Aug 24, 2026

65.1

Fundamentals Strong

Market Sentiment Bullish

Moat Narrow

Full Analysis

Key Statistics

Market Data

Market Cap $4.52B

1D Range

26.34 27.31

52W Range

19.69 30.96

Valuation (TTM)

PE 11.89

PB 3.46

EV/EBITDA 31.32

Valuation (NTM)

Forward PE 28.59

Forward PEG 0.25

Price Target $33.83

Cash Flow

FCF Yield 3.9%

SBC Adj. FCF Yield 2.5%

SBC Impact -34.1%

Margins

Gross Margin 91.1%

Operating Margin 7.6%

FCF Margin 15.3%

Growth (CAGR)

Revenue 3Y | 5Y 27.4% | 19.7%

Dil EPS 3Y | 5Y 82.0% | 254.2%

FCF 3Y | 5Y 31.9% | 149.2%

Returns

ROA 21.8%

ROE 32.4%

ROIC 6.2%

Financial Health

Net Cash

$956.47M

Current Ratio 3.39

Interest Coverage 0.00

Dividends

Div Yield N/A

Payout Ratio N/A

FCF Payout Ratio N/A

All Key Statistics

Loading financial charts...

Profile

ACADIA Pharmaceuticals Inc. operates as a biopharmaceutical company, primarily dedicated to discovering, developing, and commercializing small molecule therapeutics. Their core focus lies in addressin...

Sector Healthcare

Industry Biotechnology

Employees 797

IPO Date May 26, 2004

Website www.acadia.com

Fiscal Year January - December

Full Company Profile

Latest News

19 days ago · zacks.com

Why Is Acadia (ACAD) Up 0.5% Since Last Earnings Report?

Acadia (ACAD) reported earnings 30 days ago. What's next for the stock?

29 days ago · zacks.com

Acadia Gets European Commission Nod for Daybu in Rett Syndrome

ACAD secures EC approval for Daybu, the first and only treatment approved in the EU for Rett syndrome, expanding its geographical reach.

29 days ago · gurufocus.com

European Commission Approves DAYBU® (trofinetide) as the First and Only Treatment for Neurobehavioral Symptoms of Rett Syndrome in the European Union

Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the European Commission (EC) has granted marketing authorization for DAYBU (trofinetide) for the

29 days ago · defenseworld.net

BlackRock Inc. Purchases Shares of 22,515,173 ACADIA Pharmaceuticals Inc. $ACAD

BlackRock Inc. acquired a new stake in ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 22,515,173 shares of the biopharmaceutical company's stock, valued at approximately $569,634,000. BlackRock Inc. owned 13.15% of ACADIA Pharmaceuticals

1 month ago · marketbeat.com

ACADIA Pharmaceuticals Expands DAYBUE, NUPLAZID Reach Ahead of Key Alzheimer's Data

ACADIA Pharmaceuticals NASDAQ: ACAD outlined commercial expansion plans for its marketed therapies, DAYBUE and NUPLAZID, while highlighting upcoming clinical data for remlifanserin in Alzheimer's disease psychosis during a discussion hosted by Canaccord Genuity.

2 months ago · zacks.com

Is ACADIA Pharmaceuticals (ACAD) Outperforming Other Medical Stocks This Year?

Here is how Acadia Pharmaceuticals (ACAD) and Amneal Pharmaceuticals (AMRX) have performed compared to their sector so far this year.

2 months ago · zacks.com

Can Acadia (ACAD) Run Higher on Rising Earnings Estimates?

Acadia Pharmaceuticals (ACAD) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.

2 months ago · zacks.com

3 Medical Stocks Standing Out After Crushing Q2 Earnings Expectations

As investors look to balance growth opportunities with defensive positioning, Acadia Pharmaceuticals, CVS Health, and Eli Lilly stand out as healthcare names combining resilient business models with strong earnings momentum.

2 months ago · zacks.com

ACAD Q2 Earnings and Revenues Beat, '26 View Raised on Product Sales

Acadia beats Q2 earnings and revenue estimates as strong Daybue and Nuplazid sales lift results and prompt the company to raise its 2026 revenue outlook.